Oragenics (NYSEAMERICAN:OGEN) issued its earnings results on Wednesday. The biotechnology company reported ($0.10) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.03), Fidelity Earnings reports.
Shares of Oragenics stock traded down $0.01 during trading on Thursday, reaching $0.36. 10,785 shares of the company’s stock were exchanged, compared to its average volume of 1,193,495. Oragenics has a 1-year low of $0.36 and a 1-year high of $3.74.
Separately, HC Wainwright restated a “buy” rating and issued a $2.00 price target on shares of Oragenics in a research note on Tuesday, May 21st.
Oragenics, Inc develops novel antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients.
Read More: What is net income?
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.